Cardiff Oncology Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Cardiff OncologyDer Umsatz und der Gewinn des Unternehmens werden voraussichtlich um 48.5% bzw. 30.1% pro Jahr zurückgehen, während der Gewinn pro Aktie voraussichtlich zurückgehen wird.

Wichtige Informationen

-29.0%

Wachstumsrate der Gewinne

-19.8%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.7%
Wachstumsrate der Einnahmen	-32.6%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	06 Sep 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Aug 01

Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Feb 22

Cardiff Oncology: 41% Loss In One Day For A Best-In-Class Colorectal Cancer Treatment

Sep 14

Cardiff Oncology: Down But Not Out

Aug 22

Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Jun 20

Cardiff Oncology: Upcoming Readouts And Several Green Lights

Jun 07

Cardiff Oncology: Risky Investment

May 19

Cardiff: A Long-Term Biotech To Own Based On Overcoming Cancer Resistance

Mar 01

We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate

Jan 28

Cardiff: The Pfizer Interest Is Interesting

Dec 15

Circling Back On Cardiff Oncology

Oct 12

Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Aug 26

Cardiff Oncology: Current Slump Doesn't Look Right

Jun 14

Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Apr 29

How Much Are Cardiff Oncology, Inc. (NASDAQ:CRDF) Insiders Spending On Buying Shares?

Feb 28

What Type Of Shareholders Own The Most Number of Cardiff Oncology, Inc. (NASDAQ:CRDF) Shares?

Jan 24

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:CRDF - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	0	-77	-62	-67	4
12/31/2025	0	-57	-49	-48	5
12/31/2024	1	-47	-43	-38	5
6/30/2024	1	-41	-32	-32	N/A
3/31/2024	1	-40	-31	-30	N/A
12/31/2023	0	-41	-31	-31	N/A
9/30/2023	0	-41	-34	-33	N/A
6/30/2023	0	-40	-33	-33	N/A
3/31/2023	0	-39	-33	-32	N/A
12/31/2022	0	-39	-35	-34	N/A
9/30/2022	0	-39	-33	-32	N/A
6/30/2022	0	-38	-30	-30	N/A
3/31/2022	0	-34	-28	-27	N/A
12/31/2021	0	-28	-23	-23	N/A
9/30/2021	0	-25	-21	-21	N/A
6/30/2021	0	-23	-19	-19	N/A
3/31/2021	0	-24	-19	-19	N/A
12/31/2020	0	-23	-17	-16	N/A
9/30/2020	0	-20	-15	-14	N/A
6/30/2020	0	-20	-14	-14	N/A
3/31/2020	0	-17	-13	-13	N/A
12/31/2019	0	-17	-13	-13	N/A
9/30/2019	0	-17	-14	-14	N/A
6/30/2019	0	-16	-14	-14	N/A
3/31/2019	0	-19	-14	-14	N/A
12/31/2018	0	-19	-13	-13	N/A
9/30/2018	0	-18	-13	-13	N/A
6/30/2018	1	-18	-16	-16	N/A
3/31/2018	1	-20	N/A	-17	N/A
12/31/2017	1	-25	N/A	-23	N/A
9/30/2017	0	-31	N/A	-29	N/A
6/30/2017	0	-37	N/A	-29	N/A
3/31/2017	0	-39	N/A	-33	N/A
12/31/2016	0	-39	N/A	-31	N/A
9/30/2016	0	-38	N/A	-29	N/A
6/30/2016	0	-31	N/A	-27	N/A
3/31/2016	0	-31	N/A	-24	N/A
12/31/2015	0	-27	N/A	-22	N/A
9/30/2015	0	-25	N/A	-19	N/A
6/30/2015	0	-27	N/A	-17	N/A
3/31/2015	0	-18	N/A	-15	N/A
12/31/2014	0	-14	N/A	-13	N/A
9/30/2014	0	-11	N/A	-11	N/A
6/30/2014	0	-10	N/A	-9	N/A
3/31/2014	0	-14	N/A	-8	N/A
12/31/2013	0	-12	N/A	-7	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: CRDF wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: CRDF wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: CRDF wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: CRDFDie Einnahmen des Unternehmens werden in den nächsten 3 Jahren voraussichtlich zurückgehen (-48.5% pro Jahr).

Hohe Wachstumseinnahmen: CRDFDie Einnahmen des Unternehmens werden in den nächsten drei Jahren voraussichtlich zurückgehen (-48.5% pro Jahr).

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von CRDF in 3 Jahren voraussichtlich hoch sein wird

Cardiff Oncology Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates increase by 61%

Consensus EPS estimates upgraded to US$0.97 loss

Price target increased by 13% to US$9.03

Consensus revenue estimates increase by 48%

Price target decreased by 7.8% to US$7.68

Consensus revenue estimates fall by 50%

Recent updates

Cardiff Oncology: Paramount Data Imminent In Huge First-Line mCRC Market

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Cardiff Oncology, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Insufficient new directors

We're Hopeful That Cardiff Oncology (NASDAQ:CRDF) Will Use Its Cash Wisely

Consensus revenue estimates increase by 61%

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Cardiff Oncology, Inc., Annual General Meeting, Jun 20, 2024

Cardiff Oncology Presents Novel Preclinical Data At Aacr Annual Meeting 2024 That Supports Ongoing First-Line Ras-Mutated Mcrc Clinical Study

Cardiff Oncology: Why The Bulls Are Winning Right Now (Rating Upgrade)

Consensus EPS estimates upgraded to US$0.97 loss

We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Cardiff Oncology, Inc. Announces First Patient Dosed in Randomized First-Line RAS-Mutated Metastatic Colorectal Cancer Trial (CRDF-004)

Price target increased by 13% to US$9.03

Cardiff Oncology, Inc. Provides Clinical Update on Phase 2 Randomized Second-Line ONSEMBLE Trial in Patients with RAS-Mutated mCRC

Cardiff Oncology, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Here's Why We're Watching Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Cardiff Oncology, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Cardiff Oncology, Inc. Announces Positive Clinical Data in Pancreatic Cancer and Small Cell Lung Cancer, Including Single-Agent Activity from Onvansertib Monotherapy

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 48%

Cardiff Oncology, Inc Announces New Lead Program in First-Line Metastatic Colorectal Cancer and Expanded Pfizer Relationship

Price target decreased by 7.8% to US$7.68

Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Consensus revenue estimates fall by 50%

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates increase by 14%

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Cardiff Oncology Appoints Fairooz Kabbinavar as Chief Medical Officer

Price target decreased to US$8.49

Consensus forecasts updated

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased to US$8.49

Independent Director recently bought US$257k worth of stock

Price target decreased to US$10.70

Consensus forecasts updated

Cardiff Oncology: 41% Loss In One Day For A Best-In-Class Colorectal Cancer Treatment

Price target decreased to US$12.70

Cardiff Oncology, Inc. Announces Plans for A Randomized Trial in Metastatic Colorectal Cancer (mCRC), Durability of Responses in Ongoing Phase 1B/2 Trial in mCRC

Cardiff Oncology: Down But Not Out

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Cardiff Oncology, Inc.(NasdaqCM:CRDF) dropped from Russell 2000 Value Index

Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Cardiff Oncology: Upcoming Readouts And Several Green Lights

Cardiff Oncology: Risky Investment

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$17.00

Cardiff Oncology, Inc., Annual General Meeting, Jun 09, 2022

Cardiff Oncology, Inc. Announces Executive Changes

Cardiff Oncology Announces Updated Clinical and New Biomarker Data from Phase 2 Metastatic Castration-Resistant Prostate Cancer Trial at the AACR Annual Meeting

Consensus forecasts updated

Consensus forecasts updated

Cardiff: A Long-Term Biotech To Own Based On Overcoming Cancer Resistance

Full year 2021 earnings: EPS and revenues exceed analyst expectations

We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate

Price target decreased to US$21.00

Consensus forecasts updated

Cardiff: The Pfizer Interest Is Interesting

Third quarter 2021 earnings released: US$0.17 loss per share (vs US$0.19 loss in 3Q 2020)

Circling Back On Cardiff Oncology

Independent Director recently bought US$203k worth of stock

Chief Financial Officer recently bought US$194k worth of stock

Price target increased to US$25.33

Cardiff Oncology, Inc. Announces New Data from Phase 1B/2 Trial in KRAS-Mutated Metastatic Colorectal Cancer Showing Robust Objective Response Rate and Progression Free Survival